From the CEO's Desk
Swaroop Vakkalanka, PhD
Founder & CEO
Rhizen Pharma was founded with a vision to discover and develop novel onco-therapeutics designed to improve the quality of life of patients and drive transformative outcomes.
Rhizen is deeply committed to fulfilling this vision to address the immense unmet need that exists for patients living with cancer.
At Rhizen we practice
Fostering a culture of cutting-edge innovation as has been evidenced by our pivotal leadership in the “Targeted Drugs for Oncology” space through our focus on selective PI3K inhibitors with pathbreaking differentiation
Staying focused on the patient care with a relentless drive; tracking the evolution of cancer biology and explore remedies for challenges thrown
Creative collaboration and partnerships across global markets and research institutes
Purposeful communication to ensure the team’s focus on imaginative outcomes As we head into 2025 with aspirations to grow as full-fledged Oncology development and commercialization company,
I firmly believe we are poised to make tangible difference to cancer care and to potentially bring to market innovative medicines. This is at the core of our philosophy and shapes the values at our company.
LA CHAUX DU FONDS, Switzerland–(BUSINESS WIRE)–Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced the approval of its Investigational New Drug (IND) application by the U.S.
Rhizen Pharmaceuticals S.A. and Curon Biopharmaceutical Limited Announce an Exclusive Licensing Agreement to Develop and Commercialize Tenalisib, a Dual PI3K Delta and Gamma Inhibitor for Oncology in Greater China
Exclusive licensing agreement for the development and commercialization of Tenalisib, a dual PI3K delta & gamma inhibitor in the Greater China region.
543: Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study. (ASH 2020)
UNITY-CLL is the first randomized Phase 3 study in CLL of a PI3Ki vs. chemoimmunotherapy, and the first randomized study of a PI3Ki in treatment-naive CLL.
1155: A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma (ASH 2020)
The combination of tenalisib and romidepsin demonstrates a favorable safety profile and promising indicators of combined anti-tumour activity in patients with R/R TCL.
The Rhizen Blog